Nestle SA

Nestlé SA is a nutrition, health, and wellness company, which engages in the business of manufacturing, supplying, and producing prepared dishes and cooking aids, milk-based products, pharmaceuticals and ophthalmic goods, baby foods, and cereals. It operates through the following segments: Zone North America; Zone Europe; Zone Asia, Oceania, and Africa; Zone Latin America; Zone Greater China; Nestlé Health Science; and Nespresso. The company was founded by Henri Nestlé in 1866 and is headquartered in Vevey, Switzerland.

Amazon

Covetrus Inc

Merck

Zoetis

Despite the economic challenges of the pandemic, Americans are spoiling their pets. Profit from that hot market with these top growth stocks.

5 Hot Growth Stocks to Buy With Fido in Mind

Spending on pets in the US continues to rise. According to the APPA, spending for 2020 is projected to come in at $99 billion, up from $94 billion in 2019 and $90 billion in 2018, representing a climb of 9.4% in just two years.

People Always Spend on Their Pets

Nestle will do more acquisitions, also big ones, the food giant's chief financial officer said on Wednesday.

Nestle likely to do more big acquisitions: CFO

Nestle has increased the share of recyclable or reusable plastics to package its products to 87%, making progress toward its 100% goal by 2025, and gave examples of innovation to cut plastic waste in a media briefing on Monday.

Nestle on track to meet sustainable packaging goal

Aimmune Therapeutics

These drugmakers are in the sweet spot to provide market-beating returns.

2 Mid-Cap Healthcare Stocks to Buy Now

BRIDGEWATER, N.J., Sept. 3, 2020 /PRNewswire/ -- Nestlé Health Science, a globally recognized leader in the field of nutritional science today announced the launch of MYAACD.org, an educational platform to drive awareness of Age-Associated Cellular Decline (AACD).

Nestlé Health Science Launches Educational Platform To Build Awareness Of The Role Of Age-Associated Cellular Decline (AACD) In The Aging Process

Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.

Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up

Swiss giant adds third drug to its portfolio this year

Nestle Shells Out $2 Billion for Peanut Allergy Med

Utz Brands

Stock Markets Celebrate a Strong August; Nestle's Hungry for Aimmune as Utz Feeds IPO Investors

Aimmune Therapeutics' news of its agreement with Nestle regarding its food allergy treatment has AIMT stock soaring way higher on Monday.

Aimmune Therapeutics News: Why AIMT Stock Is Skyrocketing Today

Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares more than doubled to start out the week after reports surfaced that the company would be acquired by Nestle Health Sciences, a subsidiary of the Nestle.

Are Aimmune Shareholders Getting Enough in the Buyout?

Nestlé is buying the maker of a peanut allergy drug for children for $2.6 billion as it deepens its focus into health care and nutrition.

Nestle is paying $2.6 billion for a company that treats peanut allergies

Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment.
Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment.

Here’s why Nestlé is buying a peanut-allergy company for $2.6B

New York, New York--(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/62871_5167b93204a2486d_001full.jpgTo: All Persons or Entitie

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Aimmune Therapeutics, Inc. to Nestlé S.A.

Swiss food giant Nestle early Monday announced an agreement to buy Aimmune Therapeutics, the maker of the only approved drug to treat peanut allergies, for $2.6 billion. AIMT stock soared.

Nestle To Buy Peanut Allergy Treatment Maker Aimmune For $2.6 Billion

Nestle is gobbling up the peanut allergy drugmaker Aimmune Therapeutics for a cool $2.6 billion.

Why Aimmune Therapeutics Stock Is Soaring Today

The world’s largest consumer products company, Nestlé S.A., has agreed to acquire Aimmune Therapeutics Inc.

Nestle Adds Peanut Allergy Treatment to Its Portfolio

TAIPEI, Taiwan--(BUSINESS WIRE)--Oak Stone Limited have commented on Nestle after it announced its definitive agreement to purchase biopharma company Aimmune for $2.6 billion.

Oak Stone Limited Comments On Nestle As They Agree To Acquire Allergy Treatment Maker Aimmune For $2.6 Billion

Nestle (SWX: NESN) on Monday expressed plans of buying Aimmune Therapeutics for £1.95 billion. The Brisbane-based biopharmaceutical company is largely known for its peanut allergy treatment.

Nestle wishes to acquire Aimmune Therapeutics for £1.95 billion

Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.

Nestle pays $2 billion to secure Aimmune's allergy treatment

Nestle S.A. (OTC: NSRGY) subsidiary Nestle Health Sciences (NHSc) is aquiring biopharma company Aimmune Therapeutics, Inc.

Aimmune Shares Surge 170% As Nestle Set To Acquire Company At $2.6B Enterprise Value

Nestle said on Thursday it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own, adding a potential blockbuster to its health science portfolio.

Nestle to buy Aimmune Therapeutics for $2.6 billion

This press release is also available in Français (pdf) and Deutsch (pdf)

Nestlé to acquire Aimmune Therapeutics

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Inc.

Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science

Nestlé: Focusing Its Efforts In The Right Places

News for Nestle SA Stock (NSRGY)